Advertisement
Advertisement
Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
Bradley succeeds Patrick Healy, who will retire from the Swire Group in May next year after over three decades of service.
Survey of multinational corporations finds optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth.
Hong Kong plans to build an international gold trading centre as part of a wider commodities hub push.
US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.
Advertisement
BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.
GigaDevice and Montage are each aiming to raise as much as US$1 billion from Hong Kong listings as early as January, report says.
The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.
The three-way merger will create China’s fourth-largest investment bank with assets of US$128 billion.
New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.
Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.
Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.
Unveiling of benchmark tracking Hong Kong-listed tech firms comes amid a wave of property stock delistings.
CSRC chairman Wu Qing outlines ‘deep transformation’ of capital market to attract long-term investors who ‘can stay and can develop well’.
Latin America, which has been an underappreciated market for many years, is the stand-out performer in emerging markets.
The combined wealth of mainland China’s billionaires soars 22 per cent to US$1.77 trillion; Hong Kong’s ultra-rich population rises.
Seven cornerstone investors led by London-based M&G Investments pledge a total of US$170 million.
A wave of billion-dollar offerings is building behind four new listings this week, signalling sustained momentum in Hong Kong’s IPO market.
Share placement to help Shenyang-based firm advance clinical research in China and the US, expand reach of cancer and hair-loss drugs.
The pilot-scale platforms are aimed at helping innovators overcome hurdles in R&D and manufacturing before achieving commercial production.
Swiss bank flags five major risks for next year, including economic weakness, resurgence of inflation and renewed US-China tensions.
Gross sales reach US$82.6 billion in the first three quarters as investors pile into fixed-income funds: HKIFA.
HKMA’s Eddie Yue calls for deeper regional financial integration amid tariff shocks, disrupted supply chains and market volatility.
Growing number of men join women in embracing energy-based aesthetic treatments as a preventive measure: Sisram Medical.
As 3SBio lines up a Hong Kong spin-off for its hair-loss unit Mandi, the subsidiary is preparing a drug pipeline aimed at acne and obesity.
Trip.com co-founder James Liang says Hong Kong is uniquely placed to help solve China’s looming population crunch.
Top concerns include a potential tech bubble, geopolitical tensions and recession, according to Natixis.
Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.
Xpeng, Cherry and others expand beyond cars, with humanoid robot Iron winning praise from Tesla CEO Elon Musk.
A ‘major Saudi development company’ will host a roadshow in Hong Kong next month to seek strategic partners, financial secretary says.
